Agios Pharmaceuticals (AGIO) vs Korsana Biosciences (KRSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 262.5% versus a gain of 9.4%. Over five years, AGIO leads with a -24.3% price change compared with -89.0% for KRSA. Korsana Biosciences is the larger company by market cap ($1.71 billion vs $1.65 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +3.7%).
Korsana Biosciences converts more of its revenue into profit, with a net margin of -170.1% versus -764.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | KRSA |
|---|---|---|
| Share price | $27.60 | $37.56 |
| Market cap | $1.65B | $1.71B |
| 1-day change | -4.03% | +5.95% |
| YTD return | +1.40% | +322.50% |
| 1-year return | +9.35% | +262.55% |
| 5-year return | -24.28% | -89.05% |
| EPS (TTM) | $-6.31 | $-16.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | $2.07M |
| Revenue growth (YoY) | +48.03% | +3.70% |
| Net income (latest FY) | $-412.78M | $-3.53M |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | -239.78% |
| Net margin | -764.01% | -170.11% |
| 52-week high | $44.09 | $59.36 |
| 52-week low | $24.16 | $7.19 |
| Distance from 52-week high | -37.40% | -36.73% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.07% | +17.15% |
| Average volume | 1.06M | 119.71K |
| Shares outstanding | 59.81M | 45.54M |
| Employees | 539 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed AGIO by 253.2 percentage points over the past year.
- Korsana Biosciences is more profitable, keeping -170.1 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
- Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +3.70%).
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
AGIO vs KRSA FAQ
Which is bigger, Agios Pharmaceuticals or Korsana Biosciences?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.71B compared with $1.65B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or KRSA?
KRSA returned +262.55% over the past 12 months, compared with +9.35% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Korsana Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.